^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    tilatamig samrotecan (AZD9592) (Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, c-MET-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond

    Published date:
    04/04/2023
    Excerpt:
    AZD9592 combined with osimertinib also showed benefit in PDX models derived from patients who progressed on osimertinib alone, as well as models representing primary resistance (EGFR ex20ins).... These results demonstrate that AZD9592 has a promising efficacy and safety profile in preclinical models representing diverse opportunities in multiple clinical settings.
    DOI:
    10.1158/1538-7445.AM2023-5736